Key result
Ketorolac significantly prolonged bleeding time and inhibited platelet aggregation, with no interaction found between ketorolac and heparin.
Why the study?
Does ketorolac, alone or in combination with low dose heparin, affect haemostasis in healthy male volunteers?
RCT (n=12)
Double-blind
Does ketorolac, alone or in combination with low dose heparin, affect haemostasis in healthy male volunteers?
Ketorolac alters platelet function and bleeding time without interacting with the anticoagulant effects of low-dose heparin, suggesting it can be co-administered but requires caution in patients with bleeding risks.
Answers are grounded in this paper and cite their sources.
Supports cautious ketorolac use in bleeding-risk patients despite no heparin interaction; extends RCT evidence on haemostatic effects in volunteers.
Ketorolac is a potent cyclo-oxygenase inhibitor used for the treatment of postoperative pain. It is known to have anti-platelet properties. The aim of this study was to determine the effect of ketorolac on haemostasis both alone and in combination with low dose heparin in 12 healthy male volunteers. Each volunteer received the following drug combinations in a double blind, placebo controlled, cross over manner: ketorolac placebo/heparin placebo, ketorolac active/heparin placebo, ketorolac active/heparin active and ketorolac placebo/heparin active. Ketorolac significantly prolonged bleeding time, inhibited platelet aggregation to arachidonic acid and collagen and platelet thromboxane production. Heparin had no effect on bleeding time or platelet function, but significantly prolonged the kaolin cephalin clotting time and increased anti-Xa levels. Ketorolac had no effect on the kaolin cephalin clotting time or anti-Xa levels and no interaction was found between ketorolac and heparin in any of the investigations. The prolongation of bleeding time seen with ketorolac is unlikely, to be of any major clinical significance as almost all subjects remained within the normal range; however, it should be used with caution in subjects with haemostatic problems.
No takes yet. Share an insight, caveat, or question.
Spowart et al. (1988) conducted an RCT in Healthy volunteers (n=12). Ketorolac alone and in combination with low dose heparin vs. Placebo was evaluated on Haemostasis (bleeding time, platelet aggregation, thromboxane production, kaolin cephalin clotting time, anti-Xa levels). Ketorolac significantly prolonged bleeding time and inhibited platelet aggregation, with no interaction found between ketorolac and heparin.
Synapse has enriched 10 related papers. Consider them for comparative context: